enter
fever
foodborn
infecti
diseas
caus
salmonella
enterica
serotyp
typhi
paratyphi
b
c
high
incid
low
incom
countri
increas
risk
diseas
travel
come
high
incom
countri
pretravel
health
advic
hygien
sanit
practic
vaccin
significantli
reduc
risk
acquir
infect
although
major
case
selflimit
lifethreaten
complic
occur
delay
diagnosi
case
infect
caus
multidrug
resist
strain
complic
clinic
manag
affect
prognosi
intern
effort
need
reduc
burden
diseas
low
incom
countri
indirectli
reduc
risk
travel
endem
set
surveil
activ
help
monitor
epidemiolog
case
caus
drugsuscept
resist
strain
context
global
process
travel
pose
threat
health
million
person
worldwid
outbreak
epidem
episod
transmiss
diseas
eg
ebola
zika
middl
east
respiratori
syndrom
etc
potenti
associ
travel
popul
group
rais
attent
supran
nation
govern
base
mortal
morbid
impact
sustain
countri
region
healthcar
system
migrat
wave
busi
holiday
travel
might
epidemiolog
driver
sever
infecti
diseas
low
incid
geograph
area
involv
numer
contagi
suscept
individu
well
rapid
transfer
patient
modern
transport
mean
might
creat
epidemiolog
condit
unforeseen
outbreak
infecti
diseas
rare
geograph
area
occur
rapidli
spread
context
unprepar
nation
healthcar
system
addit
number
intern
travel
increas
global
presumpt
million
total
million
million
intern
travel
record
respect
infecti
diseas
diagnos
travel
come
asia
subsaharan
africa
latin
america
caribbean
infecti
diseas
system
eg
malaria
dengu
enter
fever
onethird
caus
gastrointestin
pathogen
eg
campylobact
spp
salmonella
spp
shigella
spp
wherea
decreas
trend
incid
malaria
record
incid
enter
dengu
fever
chang
overtim
enter
fever
includ
typhoid
paratyphoid
fever
infecti
diseas
caus
salmonella
enterica
serotyp
typhi
paratyphi
b
c
foodborn
transmiss
frequent
associ
poor
hygien
condit
inadequ
sanit
favor
outbreak
low
incom
countri
base
recent
global
estim
million
incid
case
typhoidrel
death
occur
annual
improv
sanit
live
condit
well
treatment
drink
water
significantli
contribut
decreas
incid
enter
fever
high
incom
countri
eg
locat
western
europ
north
america
indian
subcontin
southeast
asia
show
highest
annual
incid
typhoid
fever
case
per
case
annual
follow
southern
africa
per
case
annual
recent
metaanalysi
conduct
marchello
colleagu
africa
asia
identifi
highendem
countri
typhoid
fever
although
decreas
trend
incid
document
moreov
lowresourc
area
tanzania
myanmar
republ
democrat
congo
drc
typhi
repres
lead
caus
bloodstream
infect
young
children
particular
case
occur
children
year
old
year
old
drc
howev
high
incom
countri
typhoid
fever
one
frequent
diagnos
vaccineprevent
diseas
return
intern
travel
migrant
come
high
incid
countri
estim
incid
rate
typhoid
fever
travel
highendem
countri
case
per
travel
retrospect
studi
carri
netherland
found
major
patient
import
typhoid
fever
travel
asia
eg
indonesia
india
morocco
declin
annual
attack
rate
ie
annual
incid
import
case
number
travel
geograph
area
geograph
destin
except
india
describ
frequent
affect
age
group
year
accord
find
survey
perform
australia
confirm
east
south
asia
highest
risk
geograph
area
individu
visit
countri
birth
similar
find
confirm
greek
studi
highlight
risk
travel
indian
subcontin
case
travelassoci
enter
fever
especi
vfr
visit
friend
rel
travel
whose
diseas
associ
longer
stay
exposur
contamin
water
food
difficult
access
pretravel
medic
servic
due
languag
cultur
barrier
well
lower
rate
vaccin
travelrel
prevent
infect
includ
typhoid
vaccin
similarli
retrospect
studi
conduct
qatar
report
case
typhoid
fever
travel
abroad
mainli
indian
subcontin
typhoid
fever
case
europ
acquir
abroad
frequent
caus
strain
mark
antibiot
resist
profil
itali
typhoid
fever
endem
first
half
last
centuri
mean
annual
notif
rate
case
although
case
success
treat
unequ
distribut
incid
case
popul
group
age
year
found
like
link
travel
habit
travel
highto
lowand
middleincom
countri
risk
infecti
diseas
higher
vfrtravel
follow
travel
reason
migrant
low
incom
countri
repres
vulner
popul
group
highest
risk
respiratori
vectorand
foodborn
diseas
owe
higher
circul
microorgan
countri
origin
moreov
higher
risk
could
depend
long
period
stay
countri
origin
often
remot
rural
area
healthcar
infrastructur
poor
close
contact
local
popul
well
consumpt
local
food
water
frequent
travel
fromto
high
incid
countri
increas
probabl
acquir
infect
caus
mycobacterium
tuberculosi
hiv
plasmodium
spp
salmonella
spp
ten
year
surveil
uk
demonstr
lower
rate
enter
fever
ukborn
vs
migrant
popul
migrant
south
asian
countri
highest
risk
enter
fever
migrant
case
anoth
group
highest
risk
includ
person
involv
humanitarian
staf
eg
missionari
medic
humanitarian
worker
length
stay
long
travel
destin
low
incom
countri
incid
abovement
infecti
diseas
high
nevertheless
global
travepi
network
gten
data
us
show
appropri
pretravel
care
vaccin
coverag
hepat
typhoid
yellow
fever
although
epidemiolog
data
reveal
occurr
typhoid
fever
case
highincom
countri
rare
event
awar
well
knowledg
diseas
poor
uptod
estim
typhoid
fever
incid
could
use
support
prevent
vaccin
nation
strategi
moreov
help
identifi
group
high
risk
infect
plan
adequ
prevent
strategi
addit
base
poor
specif
typhoid
fever
symptom
potenti
diagnost
delay
could
increas
risk
rapid
spread
lowincid
area
nonsystemat
narr
review
retriev
scientif
evid
import
enter
ie
typhoid
paratyphoid
fever
diagnos
high
incom
countri
carri
describ
relev
clinic
public
health
featur
search
engin
pubm
use
select
peerreview
articl
publish
octob
refer
select
manuscript
care
assess
detect
import
articl
includ
primari
search
detail
select
criteria
adopt
choos
articl
follow
keyword
use
find
articl
import
enter
feverrel
diagnosi
therapi
epidemiolog
prevent
typhoid
fever
enter
fever
travel
total
record
publish
januari
octob
found
base
titl
abstract
fulltext
studi
deem
suitabl
twentythre
focus
epidemiolog
characterist
enter
fever
fourteen
vaccin
fourteen
antimicrobi
resist
salmonella
spp
serotyp
ten
popul
group
higher
risk
acquir
typhoid
fever
ten
diagnosi
treatment
risk
typhoid
fever
nontyphoid
salmonella
invas
infect
highest
infant
young
children
young
adult
underli
comorbid
includ
sever
anemia
malaria
malnutrit
hiv
infect
moreov
recent
report
intern
travel
agenc
show
immunocompromis
travel
usual
follow
itinerari
immunocompet
person
visit
countri
high
risk
infect
risk
develop
travelrel
diseas
five
time
higher
compar
immunocompet
person
howev
data
group
risk
acquir
typhoid
infect
controversi
scant
gordon
show
immunolog
statu
associ
increas
risk
poor
outcom
howev
invas
diseas
caus
nontyphoid
salmonella
frequent
diagnos
immunocompromis
person
eg
person
hivaid
likewis
studi
conduct
africa
find
differ
hivposit
patient
control
clinic
present
outcom
typhoid
fever
case
contrast
gotuzzo
colleagu
found
rate
typhoid
fever
time
higher
hivposit
patient
gener
popul
remark
increas
number
travel
highincom
countri
last
two
decad
estim
million
children
travel
oversea
everi
year
unit
state
similarli
signific
increas
travel
fold
shown
greec
high
proport
enter
fever
case
describ
children
age
year
mainli
attribut
tourism
vfrtravel
zhou
colleagu
highlight
increas
rate
childhood
enter
fever
larg
tertiari
care
center
canada
sever
case
caus
salmonella
paratyphi
b
bacteri
strain
resist
firstlin
antibiot
australia
childhood
case
acquir
mainli
southeast
asia
annual
increas
incid
period
case
per
year
period
case
per
year
similar
data
describ
franc
children
age
year
account
onethird
enter
fever
patient
infect
acquir
africa
pretravel
counsel
focus
hygien
prevent
measur
could
help
reduc
risk
infect
individu
younger
two
year
immun
current
avail
vaccin
infect
avert
vaccin
hygienerel
recommend
howev
adher
pretravel
advic
includ
vaccin
poor
sinc
world
health
organ
advoc
control
typhoid
fever
base
vaccinerel
strategi
bill
melinda
gate
foundat
launch
partnership
call
typhoid
fever
vaccin
acceler
consortium
tyvac
mainli
focus
children
live
high
endem
area
increas
prescript
typhoid
conjug
vaccin
africa
asia
current
three
typhoid
vaccin
avail
effect
current
vaccin
strategi
travel
depend
sever
variabl
previou
immun
type
length
travel
poor
awar
high
risk
foodborn
diseas
lowand
lowmiddleincom
countri
increas
pool
individu
vaccin
hesit
survey
conduct
eueea
countri
show
hepat
first
vaccin
administ
swiss
italian
travel
follow
tetanusdiphtheria
swiss
typhoidfev
vaccin
italian
travel
moreov
travel
destin
increas
request
pretravel
care
eg
india
thailand
chosen
pleasur
busi
furthermor
low
vaccin
uptak
inappropri
precaut
adopt
vfrtravel
associ
highest
incid
foodborn
diseas
greek
survey
focus
administr
typhoid
fever
vaccin
show
high
proport
travel
india
accept
prescript
vaccin
comparison
lower
percentag
individu
travel
africa
live
attenu
vaccin
develop
attenu
strain
typhi
confer
protect
singl
dose
three
dose
administ
altern
day
person
live
endem
countri
four
dose
travel
usual
recommend
elicit
adapt
mucos
immun
iga
antibodi
whose
durat
year
vaccin
case
half
typhoid
fever
case
could
prevent
three
year
vaccin
purifi
vi
capsular
polysaccharid
vaccin
administ
one
singl
dose
associ
high
immunogen
adult
children
older
two
year
nevertheless
anwar
colleagu
report
prevent
effect
one
third
one
half
case
first
two
year
vaccin
clear
benefit
three
year
moreov
accept
immunogen
safeti
profil
shown
coadminist
yellowfev
quadrival
meningococc
vaccin
well
children
hivposit
individu
second
dose
recommend
three
year
purifi
vi
polysaccharid
vaccin
conjug
toxoid
vidiphtheria
vitetanu
virecombin
diphtheria
crm
increas
igg
level
twoyear
postvaccin
effect
singl
random
trial
indian
children
age
six
month
year
clarifi
efficaci
two
dose
vitt
vaccin
one
year
administr
reallif
survey
germani
describ
advers
event
rate
fatigu
pain
headach
pyrexia
myalgia
swell
increas
concomit
immun
vaccin
ie
rabi
typhoid
yellow
fever
vaccin
us
militari
studi
show
advers
event
individu
expos
polysaccharid
vi
vaccin
comparison
expos
oral
vaccin
although
rash
diarrhea
incid
latter
group
fever
pain
inject
site
incid
use
parenter
vaccin
sever
studi
suggest
crossprotect
paratyphi
b
c
administr
oral
vaccin
common
oand
viantigen
even
studi
recruit
us
militari
personnel
describ
weak
immun
paratyphi
primari
prevent
base
avail
vaccin
implement
youngest
children
purifi
vi
capsular
polysaccharid
vaccin
recommend
children
age
year
poor
immunogen
live
attenu
oral
vaccin
well
toler
children
age
five
year
recent
review
efficaci
current
avail
vaccin
confirm
vi
polysaccharid
vaccin
reduc
incid
infect
adult
children
age
year
clinic
manag
typhoid
fever
travel
significantli
chang
last
two
decad
follow
widespread
distribut
mdr
bacteria
increas
number
intern
travel
endem
countri
includ
highrisk
individu
eg
children
immunocompromis
patient
pregnant
women
elderli
peopl
although
ill
travel
usual
sever
selflimit
urgent
therapi
need
avoid
lifethreaten
complic
rapid
diagnosi
therapi
return
travel
key
avoid
fatal
consequ
inform
type
travel
includ
collect
detail
accommod
activ
well
pretravel
immun
could
help
differenti
diagnosi
eg
malaria
dengu
preval
symptom
case
typhoid
infect
fever
diarrhea
vomit
abdomin
pain
headach
howev
specif
poor
attribut
viral
bacteri
agent
children
adult
moreov
higher
level
creactiv
protein
also
found
case
dengu
malaria
typhoid
fever
commonli
character
gastrointestin
disord
moreov
bradycardia
eosinopenia
empir
therapi
need
case
sever
symptom
rapid
diagnosi
perform
recommend
intern
guidelin
definit
diagnosi
typhoid
fever
requir
cultur
molecular
method
specimen
collect
ideal
administr
antimicrobi
therapi
blood
prefer
specimen
although
serolog
test
frequent
request
sever
studi
highlight
poor
specif
sensit
antimicrobi
suscept
test
strongli
recommend
clinic
prescript
tailor
antibiot
therapi
public
health
surveil
purpos
epidemiolog
investig
key
identif
sourc
case
contagi
patient
serotyp
carri
slide
agglutin
method
character
genom
profil
use
puls
field
gel
electrophoresi
pfge
multi
locu
sequenc
type
mlst
recommend
confirm
epidemiolog
link
suspect
outbreak
era
multidrug
resist
strain
adopt
antimicrobi
suscept
test
necessari
guid
choic
appropri
therapi
improv
clinic
manag
prevent
relaps
chronic
carrier
statu
european
committe
antimicrobi
suscept
test
eucast
clinic
laboratori
standard
institut
clsi
recommend
use
follow
antibiot
test
vitro
infect
caus
typhi
paratyphi
ampicillin
chloramphenicol
cotrimoxazol
ciprofloxacin
ceftriaxon
azithromycin
tabl
patient
usual
treat
oral
antibiot
antipyret
support
therapi
parenter
antibiot
prescrib
complic
case
gastrointestin
symptom
persist
ciprofloxacin
mgkg
day
prescrib
case
moder
symptom
caus
fulli
suscept
isol
emerg
multidrug
resist
strain
first
line
treatment
repres
third
gener
cephalosporin
cefixim
mgkg
max
mg
day
altern
drug
chloramphenicol
mgkgday
day
trimethoprimsulfamethoxazol
mgkgday
day
amoxicillin
mgkgday
day
case
sever
enter
fever
character
delirium
stupor
coma
obtund
success
treat
corticosteroid
eg
intraven
dexamethason
initi
dose
mgkg
follow
mgkg
everi
six
hour
two
day
case
typhoid
fever
world
health
organ
recommend
notif
nation
author
drug
suscept
test
multidrug
resist
strain
emerg
spread
second
half
chloramphenicol
ampicillin
cotrimoxazol
consid
firstlin
therapi
typhoid
fever
global
indiscrimin
use
antibiot
particularli
lowincom
area
favor
select
spread
antimicrobi
resist
strain
first
outbreak
caus
chloramphenicolresist
typhi
occur
mexico
follow
notif
endem
area
ie
south
asia
andafrica
moreov
isol
european
countri
show
decreas
suscept
ciprofloxacin
although
consid
past
first
therapeut
choic
world
health
organ
guidelin
us
case
typhoid
fever
patient
recent
travel
pakistan
caus
extens
drug
resist
strain
data
us
antimicrobi
monitor
system
show
isol
reduc
suscept
ciprofloxacin
nalidix
acid
well
alarm
increas
trend
resist
typhi
paratyphi
tabl
britto
colleagu
systemat
review
histor
trend
drug
resist
firstlin
antimicrobi
therapi
typhoid
fever
isol
tabl
major
isol
south
asia
africa
southeast
asia
moreov
signific
increas
trend
drug
resist
describ
nalidix
acid
fluoroquinolon
increas
rate
typhi
isol
resist
quinolon
ampicillin
cotrimoxazol
prompt
polici
chang
term
antibiot
prescript
mainli
focus
thirdgener
cephalosporin
strain
multidrug
resist
mdr
salmonella
typhi
haplotyp
found
worldwid
account
multipl
outbreak
endem
countri
singl
case
intern
travel
moreov
klemm
colleagu
detect
sever
resist
gene
extendedspectrum
gene
esbl
extensivelydrug
resist
strain
previous
detect
enter
bacteria
resist
mainli
associ
cumul
mutat
quinolon
resistancedetermin
region
qrdr
encod
dna
gyras
gyra
gyrb
gene
topoisomeras
parc
pare
gene
recent
studi
analyz
isol
typhi
found
reduc
suscept
fluoroquinolon
frequent
associ
point
mutat
qrdr
howev
preval
vari
depend
geograph
south
asia
eastafrica
westafrica
strain
resist
ciprofloxacin
mainli
collect
patient
diagnos
india
account
total
indian
case
qnrfamili
gene
respons
plasmidmedi
quinolon
resist
confer
resist
nalidix
acid
recommend
surrog
marker
decreas
suscept
ciprofloxacin
recent
report
highincom
countri
describ
trend
decreas
suscept
sever
antimicrobi
drug
ciprofloxacinresist
strain
itali
switzerland
spain
respect
antimicrobi
resist
frequent
report
usa
strain
isol
resist
nalidix
acid
show
reduc
suscept
ciprofloxacin
mdr
show
extens
drug
resist
furthermor
poor
antimicrobi
suscept
found
parathypi
typhi
isol
drug
resist
quinolon
detect
isol
paratyphi
typhi
respect
third
gener
cephalosporin
eg
ceftriaxon
success
prescrib
infect
caus
ciprofloxacinresist
strain
altern
meropenem
aztreonam
administ
even
clinic
breakpoint
aztreonam
current
avail
furthermor
isol
typhi
collect
netherland
show
resist
ciprofloxacin
azithromycin
reduc
avail
effect
therapeut
option
mainli
travel
acquir
infect
endem
set
basi
world
health
organ
recommend
manag
sporad
case
typhoid
fever
diagnos
highincom
countri
perform
refer
center
comprehens
assess
includ
complet
drug
suscept
test
could
carri
present
narr
review
highlight
typhoid
fever
import
clinic
public
health
issu
return
travel
intern
effort
cooper
activ
plan
reduc
burden
foodborn
diseas
includ
typhoid
fever
lowand
middleincom
countri
address
key
role
play
global
surveil
system
particular
reliabl
realtim
estim
typhoid
fever
help
better
assess
efficaci
costeffect
ad
hoc
activ
realiz
low
high
endem
countri
knowledg
healthcar
worker
travel
relateddiseas
improv
focus
import
rapid
diagnosi
includ
rapid
drug
suscept
test
identif
difficulttotreat
case
eg
patient
typhoid
fever
caus
multidrug
resist
strain
primari
prevent
strategi
pretravel
health
advic
could
decreas
risk
acquir
infect
improv
awar
commun
member
could
support
improv
adher
mainli
highli
suscept
group
eg
children
immunocompromis
patient
nevertheless
epidemiolog
studi
focus
effect
current
avail
vaccin
popul
group
poorli
evalu
studi
trial
carri
past
intern
surveil
network
involv
endem
countri
need
rapidli
detect
emerg
spread
drugresist
bacteria
decreas
incid
import
case
highincom
countri
financi
econom
impact
endem
diseas
easili
reduc
improv
hygien
condit
constrainedresourc
countri
howev
improv
polit
econom
issu
achiev
comprehens
intervent
support
intern
commun
directli
indirectli
affect
epidemiolog
lifethreaten
diseas
